Acetaminophen or Tylenol? A Retrospective Analysis of Medication Digital Communication Practices

David Ouyang, Rebecca L. Tisdale, Euan A. Ashley, Jeffrey Chi, Jonathan H. ChenJournal of General Internal Medicine 2018 · DOI

Introduction

In modern healthcare, nomenclature is more than a matter of semantics; it is a matter of economics and patient safety. While medical education rigorously emphasizes the use of generic (nonproprietary) names to ensure clarity and reduce costs, a "hidden curriculum" often persists within the clinical environment. This informal culture of communication frequently favors brand names, which can inadvertently lead to higher healthcare costs and potential confusion during care transitions.

This study investigates the "naming sentiment" of healthcare providers by analyzing over one million digital text pages at a major academic medical center. By examining informal, peer-to-peer communication, researchers sought to understand how deeply brand-name usage is embedded in the multidisciplinary team and what factors drive these linguistic choices.

Methodology

The researchers conducted a large-scale retrospective analysis of digital communications at Stanford University Hospital between June 2013 and April 2017. The dataset comprised 1,048,576 text pages sent to internal medicine residents. Using a high-throughput algorithmic approach, the team identified 102,243 pages specifically related to medications.

The analysis focused on 62 unique active ingredients that appeared frequently in the dataset. Researchers utilized Python for text processing and R for statistical modeling to perform a multivariate analysis. The primary variables of interest included the sender’s occupation (e.g., nurse, pharmacist, physician) and the linguistic characteristics of the drug names, such as syllable count and phonetic complexity. This methodology allowed for a "proxy" measurement of naming fluency in a real-world, unfiltered setting.

Results: The Professional and Linguistic Divide

The study revealed a significant disparity in how different healthcare professionals communicate about medications. One of the most striking findings was the "professional divide": nurses were found to be substantially more likely to use trade names compared to pharmacists. Specifically, the odds ratio for trade name usage by nurses versus pharmacists was 39.9 (95% CI 26.5–53.3).

Ratio of generic to brand name usage across different medications and healthcare professions.

Beyond professional roles, linguistic factors played a decisive role in naming conventions. The researchers identified a "brevity bias," where the complexity of a generic name directly influenced the likelihood of a brand name being used. If a generic name was significantly longer or more difficult to type than its brand-name counterpart—such as ondansetron versus Zofran—clinicians instinctively opted for the shorter version. A higher syllable count in the generic name compared to the trade name was associated with a three-fold increase in the odds of brand-name usage (OR 3.1).

As shown in Figure 3, certain medications exhibit extreme brand-name dominance. For drugs like Zofran (ondansetron) or Haldol (haloperidol), the brand name appeared nearly 100 times for every single mention of the generic name in nursing communications. Conversely, medications like NPH insulin or albuterol maintained a high ratio of generic naming across all professions.

Discussion and Implications

The findings suggest that the preference for brand names is not merely a result of physician habit or pharmaceutical marketing, but is reinforced by the practicalities of informal communication across the entire healthcare team. In the fast-paced environment of a hospital, where text pages are often character-limited and sent under time pressure, efficiency frequently trumps formal nomenclature.

This "hidden curriculum" of brand-name usage has several implications. First, it highlights that educational interventions aimed at promoting generic naming must target the entire multidisciplinary team, including nursing and pharmacy staff, rather than focusing solely on medical students and residents. Second, the study suggests that structural changes in Electronic Medical Records (EMRs) and communication platforms—such as auto-completing generic names or standardizing nomenclature—could help shift the culture toward safer and more cost-effective naming practices.

Limitations

The study is subject to several limitations. As a single-center study conducted at Stanford, the results may reflect local institutional culture and may not be fully generalizable to other healthcare settings. Additionally, the "pager effect"—the inherent need for brevity in text-based communication—might exaggerate the preference for shorter brand names. It remains unclear whether the use of brand names in informal texts directly translates to brand-name prescribing at the pharmacy counter, a topic that warrants further investigation.

Conclusion

The transition from "Tylenol" to "acetaminophen" in clinical discourse requires more than just classroom instruction. It requires an understanding of the linguistic and professional pressures that shape daily communication. By addressing these underlying drivers, healthcare systems can work toward a more standardized and cost-effective approach to medication management.

Summary updated

BibTeX
@article{ouyang2018acetaminophen,
  author = {David Ouyang and Rebecca L. Tisdale and Euan A. Ashley and Jeffrey Chi and Jonathan H. Chen},
  title = {{Acetaminophen or Tylenol? A Retrospective Analysis of Medication Digital Communication Practices}},
  journal = {Journal of General Internal Medicine},
  year = {2018},
  doi = {10.1007/s11606-018-4455-1},
}
Figure